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Abstract
A recent publication in Lancet by Dr. David Margolis and colleagues raised the prospect that HIV
infection may be curable. In this pilot study, which received much attention from the press, Dr.
Margolis'group found that valproic acid plus enfuvirtide reduces the pool of CD4+ T-cells, which
are latently infected with HIV-1, the so-called viral reservoir. This commentary critically addresses
current data on this topic.
A recent publication in Lancet [1] has created quite a stir
among HIV circles (no, not those containing 1 or 2-LTRs)
[2] and the lay press. In a study led by Dr. David Margolis,
four patients, each of whom had undetectable HIV plasma
viral loads, had enfuvirtide and valproic acid (VPA) added
to their anti-HIV regimens. The researchers measured sev-
eral parameters with particular interest in the effect of VPA
on resting CD4+ T-cells latently infected with HIV-1. This
pool of cells – often referred to as the viral reservoir – is
thought to pose an significant obstacle to HIV eradication.
Drs. Finzi, Siliciano, and colleagues first described these
CD4+ T-cells that produce little or no viral proteins but
can be stimulated with mitogens to produce infectious
virus [3]. This pool of cells is also thought to serve as a bio-
logical library for archival strains of drug-resistant HIV [4].
Even years after discontinuation of a given drug, resistant
strains of HIV-1 quickly re-emerge when the drug is re-
introduced into a therapeutic regimen. Therefore, in the-
ory, a treatment protocol that reduces or eliminates this
pool of infected cells could eliminate drug-resistant
strains, and would have the potential to cure HIV infec-
tion. However, in the absence of effective drug interven-
tion, there is little chance of eliminating this viral
reservoir; the half-life and pool size of latently infected
CD4+ T-cells are considered too great to permit eradica-
tion under current regimens in most, if not all, patients.
Dr. Siliciano and colleagues estimate the mean time to
eradication is 51.2 years in the best case scenario [5], e.g.,
those patients who have undetectable viral loads and no
viral "blips."
Dr. Margolis' laboratory previously demonstrated that
VPA can stimulate the release of virus from latently
infected CD4+ T-cells in vitro [6]. The stimulatory effect of
VPA is equal to, or greater than, that of the mitogen, PHA,
but VPA has no effect on T-cell activation or virus produc-
tion from mitogen-activated lymphoblasts. VPA inhibits
histone deacetylase (HDAC)-1, which may be involved in
suppressing HIV promoter activity in latently infected,
resting CD4+ T-cells. In the Lancet study, four patients with
long-term, undetectable viremia were given enfuvirtide,
an injectable HIV fusion inhibitor, added to their ongoing
regimens. After 4–6 weeks, VPA was then started. The VPA
dose (500–750 mg twice per day) was adjusted to main-
tain plasma concentrations within a defined range (50–
100 mg/L). The frequency of infection in resting CD4+ T-
cells was measured twice at baseline prior to initiation of
VPA therapy, and again 12 weeks after the start of VPA
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treatment. While baseline measurements showed little or
no change in the frequency of latently infected CD4+ T-
cells, enfuvirtide and VPA therapy decreased this measure-
ment by 29–84% in all four subjects. No changes were
observed in the frequency of HIV proviral DNA or
immune activation markers. The authors conclude that
HDAC inhibitors, such as VPA, could lead to HIV eradica-
tion when combined with other anti-HIV drugs.
The results of this pilot study are intriguing, but must be
considered cautiously with a clear understanding of their
inherent limitations. By design, the study was not control-
led and each patient received two new drugs, enfuvirtide
and VPA, and the relative contribution of each drug to
lowering the frequency of latently infected CD4+ T-cells is
unknown. At least one group has demonstrated that
intensification of anti-HIV therapy decreases the half-life
of this population [7]. Moreover, absolute CD4+ T-cell
counts can vary significantly even in stable patients with
undetectable viral loads, and this variability may influ-
ence quantitative assessments of the latent pool of
infected cells. While the reported decrease in latently
infected CD4+ T-cells in the four patients receiving VPA is
certainly promising, further evaluations of the efficacy of
VPA in combination with other anti-HIV drugs will be
needed in larger, controlled clinical studies.
This study also raises important issues regarding the use of
enfuvirtide in an intensification regimen. As reported, two
patients had residual viremia after intensification with
enfuvirtide making it unclear whether this intensification
is necessary or especially beneficial. Theses data suggest
that intensification may not be necessary or helpful, or
more importantly, that reduction of the reservoir pool
may occur in the presence of on-going, low level viral rep-
lication. Presumably this issue will be addressed in future
studies.
Of considerable interest is the potential mechanism by
which VPA reduces the frequency of latently infected, rest-
ing CD4+  T-cells. Presumably, through inhibition of
HDAC, VPA allows initiation of viral transcription, which
in turn leads to production of viral proteins and virions,
and cell death due to virally induced cytotoxicity. Para-
doxically, VPA does not activate resting CD4+ T-cells, thus
making it unclear how HIV transcription is upregulated
and viral promoter activity is increased.
In this regard, many critical questions remain to be
answered. Foremost, what happens to the pool of latently
infected cells after enfuvirtide and VPA are discontinued?
Data by Dr. Margolis and colleagues have shown VPA
works quickly in vitro to induce virus production from
latently infected cells. In vivo, very few new latently
infected cells would be expected to develop over the dura-
tion of VPA treatment presented in their Lancet study. And
yet a proportion of latently infected cells remained after 3
months of therapy. Do these remaining cells represent a
distinct subset from those eliminated by enfuvirtide and
VPA? Viral RNA clearance has two phases of decay [8].
Does the population of latently infected CD4+ T-cells have
similarly complicated kinetics?
Others have tried to reduce the latent viral reservoir, pri-
marily through activation of resting CD4+ T-cells. In one
sobering example, Drs. Fauci, Chun, Lane and colleagues
stopped anti-HIV medications in two patients, who had
undetectable viral loads for years and had received IL-2
therapy [9,10]. At the time HIV therapy was discontinued
virus could not be cultured from resting CD4+ T-cells,
either from the blood or lymph nodes, of either patient.
More significantly, proviral DNA was below the limit of
detection (0.5 copies per 106  PBMC). Despite these
impressive laboratory findings, within three weeks,
plasma HIV RNA levels became detectable and rose above
10,000 copies per ml.
Finally, the assumption that the population of latently
infected, resting CD4+ T-cells is the only reservoir for HIV-
1 in vivo is largely untested. While the persistence of these
cells likely guarantees chronic infection, their elimination
may not result in eradication. Other pools of HIV-infected
cells or tissue reservoirs may exist. While current results
presented in the Lancet study certainly provide reason to
be optimistic, it is critical to balance this optimism with
further rigorous clinical evaluations, including larger,
controlled studies of VPA and enfuvirtide. As always, the
results of any pilot study must be interpreted with caution
and placed in the proper context of existing knowledge. It
is my hope that Dr. Margolis and colleagues are correct,
and that HIV reservoirs can be eliminated through the
additional administration of a small molecule, such as
VPA. However, the challenge of eradicating HIV remains
daunting, and history and science have yet to yield simple
answers.
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